NO20002526D0 - Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav - Google Patents

Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav

Info

Publication number
NO20002526D0
NO20002526D0 NO20002526A NO20002526A NO20002526D0 NO 20002526 D0 NO20002526 D0 NO 20002526D0 NO 20002526 A NO20002526 A NO 20002526A NO 20002526 A NO20002526 A NO 20002526A NO 20002526 D0 NO20002526 D0 NO 20002526D0
Authority
NO
Norway
Prior art keywords
modified
preparation
methods
oral dosage
release oral
Prior art date
Application number
NO20002526A
Other languages
English (en)
Other versions
NO20002526L (no
NO329206B1 (no
Inventor
Gopadi M Venkatesh
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20002526L publication Critical patent/NO20002526L/no
Publication of NO20002526D0 publication Critical patent/NO20002526D0/no
Publication of NO329206B1 publication Critical patent/NO329206B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20002526A 1997-11-17 2000-05-16 Granulering og preparat med hoyt legemiddelinnhold, fremgangsmate for fremstilling derav og farmasoytisk preparat. NO329206B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6591897P 1997-11-17 1997-11-17
PCT/US1998/024502 WO1999025321A1 (en) 1997-11-17 1998-11-17 High drug load immediate and modified release oral dosage formulations and processes for their manufacture

Publications (3)

Publication Number Publication Date
NO20002526L NO20002526L (no) 2000-05-16
NO20002526D0 true NO20002526D0 (no) 2000-05-16
NO329206B1 NO329206B1 (no) 2010-09-13

Family

ID=22066009

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002526A NO329206B1 (no) 1997-11-17 2000-05-16 Granulering og preparat med hoyt legemiddelinnhold, fremgangsmate for fremstilling derav og farmasoytisk preparat.

Country Status (14)

Country Link
EP (1) EP1033974B1 (no)
JP (1) JP4880118B2 (no)
KR (1) KR100597922B1 (no)
CN (1) CN1285739A (no)
AU (1) AU750611B2 (no)
BR (1) BR9814877A (no)
CA (1) CA2310028C (no)
HU (1) HUP0004407A3 (no)
IL (1) IL136142A0 (no)
NO (1) NO329206B1 (no)
NZ (1) NZ504565A (no)
PL (1) PL340587A1 (no)
TR (1) TR200001412T2 (no)
WO (1) WO1999025321A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004862A2 (en) * 1998-07-20 2000-02-03 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
EP1790334A3 (en) * 1999-11-02 2008-02-20 Depomed, Inc. Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB0228878D0 (en) * 2002-06-21 2003-01-15 Unilever Plc Hair conditioning composition
EP3045174A1 (en) 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
AU2007249399A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP5653218B2 (ja) * 2007-11-06 2015-01-14 ノバルティス アーゲー アンジオテンシン受容体アンタゴニスト／ブロッカーおよび中性エンドペプチダーゼ（ｎｅｐ）阻害剤の超構造に基づく二作用性医薬組成物
AR072477A1 (es) * 2008-07-11 2010-09-01 Solvay Pharm Bv Formulacion farmaceutica de eprosartan. uso.
JP5476782B2 (ja) * 2009-04-21 2014-04-23 大正製薬株式会社 アルギニン含有錠剤の製造方法
JP5446716B2 (ja) * 2009-10-21 2014-03-19 大正製薬株式会社 アルギニン及びカルニチン含有錠剤の製造方法
TR201007508A1 (tr) * 2010-09-14 2012-04-24 Sanovel İlaç San. Ve Ti̇c. A.Ş. Oral yolla dağılan bileşimler
CN104546779A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 高药物荷载的枸橼酸西地那非片剂及其制备方法
EP3694491A1 (en) 2017-10-10 2020-08-19 Capsugel Belgium NV Gelling multiparticulates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
AU9137791A (en) * 1990-12-14 1992-07-08 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
JPH09503751A (ja) * 1993-08-02 1997-04-15 プリズム ファーマシュティカルズ，インコーポレイティド 細胞毒性抱合体の単一起源性製剤
ATE239723T1 (de) * 1996-03-29 2003-05-15 Smithkline Beecham Corp Eprosartandihydrat und ein verfahren zu seiner herstellung und formulierung

Also Published As

Publication number Publication date
CN1285739A (zh) 2001-02-28
AU1588799A (en) 1999-06-07
HUP0004407A1 (hu) 2002-02-28
IL136142A0 (en) 2001-05-20
KR100597922B1 (ko) 2006-07-10
EP1033974A1 (en) 2000-09-13
EP1033974A4 (en) 2007-05-02
NO20002526L (no) 2000-05-16
WO1999025321A1 (en) 1999-05-27
CA2310028C (en) 2008-06-10
NZ504565A (en) 2002-11-26
JP4880118B2 (ja) 2012-02-22
KR20010032129A (ko) 2001-04-16
CA2310028A1 (en) 1999-05-27
PL340587A1 (en) 2001-02-12
NO329206B1 (no) 2010-09-13
EP1033974B1 (en) 2014-01-22
TR200001412T2 (tr) 2000-09-21
JP2001522872A (ja) 2001-11-20
HUP0004407A3 (en) 2002-03-28
BR9814877A (pt) 2000-10-03
AU750611B2 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
NO20003218D0 (no) Oralfarmasøytisk doseringsform med forlenget frigivningsvirkning
NO20003219D0 (no) Oralfarmasøytisk doseringsform med pulsert frigivningsvirkning
DK0797991T3 (da) Lægemiddelformulering med forhalet frigivelse
BR9610153A (pt) Formulações farmacêuticas
BR9611626A (pt) Formulações farmacéuticas
DK0754061T3 (da) Ny oral farmaceutisk doseringsform
DE59712959D1 (de) Orale pharmazeutische zubereitung enthaltend ibandronat
NO943761L (no) Oralt administrerbare opioide formuleringer med forlenget effektvarighet
DE10199046I2 (de) Rapamycin-Zubereitungen zur oralen Verabreichung
DE69525148D1 (de) Pharmazeutische formulierung
NO993887L (no) Farmasöytiske formuleringer som innbefatter amoksycillin og clavulanat
NO992339L (no) Farmasöytiske formuleringer
NO20002526L (no) Mellomprodukt med høyt legemiddelinnhold og orale doseringspreparater med modifisert frigivelse samt fremgangsmÕter for fremstilling derav
PT868911E (pt) Formulacoes de rapamicina para administracao oral
NO950134D0 (no) Formuleringer for oralt administrerte farmasöytiske midler
ID16781A (id) Formulasi-formulasi farmasi
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
NO996044L (no) Rapamycinformuleringer for oral administrasjon
ITMI941169A0 (it) Formulazioni farmaceutiche
IT1291340B1 (it) Formulazioni farmaceutiche contenenti colostro e uso del colostro per il trattamento di affezioni del cavo orale
NO992999D0 (no) Farmas°ytisk blanding for oral administrering
DE19681529D2 (de) Pharmazeutische Darreichungsform
NO20003284D0 (no) Farmasøytisk preparat for oral administrering
SE9404467D0 (sv) Drug formulations
SE9502453D0 (sv) Drug formulations

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees